The Rationale for Prandial Glycemic Control in Diabetes Mellitus

Insulin

Volumn 2, Issue 2, 2007, Pages 52-60

  Perkins, Jennifer M ^a   Davis, Stephen N ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

cardiovascular disease; macrovascular disease; oxidative stress; postprandial hyperglycemia

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN; INCRETIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ADD ON THERAPY; ARTICLE; BLOOD CLOTTING; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DATA ANALYSIS; DIABETES MELLITUS; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOGLYCEMIA; INFORMATION RETRIEVAL; MEDLINE; MICROANGIOPATHY; NAUSEA; OXIDATIVE STRESS; PRACTICE GUIDELINE; RISK REDUCTION; SIDE EFFECT; VASCULAR DISEASE;

EID: 34548284906     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(07)80016-9     Document Type: Article

References (70)

1. 2005. Available at:. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the US. Accessed September 6, 2006. (2005), US Dept of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Go. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf
2. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham Study. JAMA 241 (1979) 2035-2038
3. Coutinho M., Gerstein H.C., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 22 (1999) 233-240
4. Bellodi G., Manicardi V., Malavasi V., et al. Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am J Cordial. 64 (1989) 885-888
5. Gray C.S., Taylor R., French J.M., et al. The prognostic value of stress hyperglycaemia and previously unrecognized diabetes in acute stroke. Diabet Med. 4 (1987) 237-240
6. Bonora E., and Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: The epidemiological evidence. Diabetologia 44 (2001) 2107-2114
7. American Diabetes Association. Postprandial blood glucose. Diabetes Care. 24 (2001) 775-778
8. Pfeifer M.A., Halter J.B., and Porte Jr. D. Insulin secretion in diabetes mellitus. Am J Med. 70 (1981) 579-588
9. Mooradian A.D., and Thurman J.E. Drug therapy of postprandial hyperglycaemia. Drugs 57 (1999) 19-29
10. Pyorala K., Savolainen E., Lehtovirta E., et al. Glucose tolerance and coronary heart disease: Helsinki policemen study. J Chronic Dis. 32 (1979) 729-745
11. [published correction appears in Diabetologia. 1999;42:1444]. Shaw J.E., Hodge A.M., de Courten M., et al. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42 (1999) 1050-1054
12. Jackson C.A., Yudkin J.S., and Forrest R.D. A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community.The Islington Diabetes Survey. Diabetes Res Clin Proct. 17 (1992) 111-123
13. Meigs J.B., Nathan D.M., D'Agostino Sr. R.B., Wilson P.W., and Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: The Framingham Offspring Study. Diabetes Care 25 (2002) 1845-1850
14. Hanefeld M., Fischer S., Julius U., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia. 39 (1996) 1577-1583
15. Shichiri M., Kishikawa H., Ohkubo Y., and Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 23 Suppl 2 (2000) B21-B29
16. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA(1c). Diabetes Care. 26 (2003) 881-885
17. The Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe (DECODE) Study Group and the European Diabetes Epidemiology Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 354 (1999) 617-621
18. Avignon A., Radauceanu A., and Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20 (1997) 1822-1826
19. Feinglos M.N., Thacker C.H., English J., et al. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 20 (1997) 1539-1542
20. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329 (1993) 977-986
22. Nathan D.M., Cleary P.A., Backlund J.Y., et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive dia betes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 353 (2005) 2643-2653
23. [published correction appears in Circulation. 2003;108:500]. Heitzer T., Schlinzig T., Krohn K., et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104 (2001) 2673-2678
24. Ceriello A., Quagliaro L., D'Amico M., et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 51 (2002) 1076-1082
25. West I.C. Radicals and oxidative stress in diabetes. Diabet Med. 17 (2000) 171-180
26. Gerich J.E. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 163 (2003) 1306-1316
27. Ceriello A., Bortolotti N., Matz E., et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: The possible role of hyperglycemia. Metabolism 48 (1999) 1503-1508
28. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 26 (2003) 1589-1596
29. Ceriello A. Oxidative stress and diabetes-associated complications. Endocr Proct. 12 Suppl 1 (2006) 60-62
30. [published correction appears in Lancet. 1999;354:602]. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
31. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18 (1995) 258-268
32. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetesmellitus: A randomized prospective 6-year study. Diabetes Res Clin Proct. 28 (1995) 103-117
33. Jones R.L., and Peterson C.M. Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon. J Clin Invest. 63 (1979) 485-493
34. Ceriello A., Giugliano D., Quatraro A., et al. Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism 38 (1989) 1162-1163
35. Ceriello A., Giugliano D., Quatraro A., et al. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 31 (1988) 889-891
36. Ceriello A., Giacomello R., Stel G., et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 44 (1995) 924-928
37. Ceriello A., Falleti E., Bortolotti N., et al. Increased circulating intercellular adhesion molecule-1 levels in type II diabetic patients: The possible role of metabolic control and oxidativestress. Metabolism 45 (1996) 498-501
38. Mero N., Syvanne M., and Taskinen M.R. Postprandial lipid metabolism in diabetes. Atherosclerosis 141 Suppl 1 (1998) S53-S55
39. Heine R.J., and Dekker J.M. Beyond postprandial hyperglycaemia: Metabolic factors associated with cardiovascular disease. Diabetologia 45 (2002) 461-475
40. Teno S., Uto Y., Nagashima H., et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 23 (2000) 1401-1406
41. American Diabetes Association. Clinical practice recommendations 1995. Position statement Standards of medical care for patients with diabetes mellitus. Diabetes Care 18 Suppl 1 (2005) S8-S15
42. de Backer G., Ambrosioni E., BorchJohnsen K., et al. European Guidelines on Cardiovascular Disease Prevention in the Clinical Practice. Third work group of the European societies and other societieson cardiovascular disease prevention in the clinical practice [in Spanish]. Neurologio 19 (2004) 440-450
43. American College of Endocrinology. Consensus statement on guidelines for glycemic control. Endocr Proct. 8 Suppl 1 (2002) S5-S11
44. Breuer H.W. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Phormocol Ther. 41 (2003) 421-440
45. Chiasson J.L., Josse R.G., Gomis R., et al., STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 290 (2003) 486-494
46. Hanefeld M., Chiasson J.L., Koehler C., et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35 (2004) 1073-1078
47. Laube H. Acarbose: An update of its therapeutic use in diabetes treatment. Clin Drug Invest 22 (2002) 141-156
48. Drent M.L., Tollefsen A.T., van Heusden F.H., et al. Dose-dependent efficacy of miglitol, an alphaglucosidase inhibitor, in type 2 diabetic patients on diet alone: Results of a 24-week double-blind placebo-controlled study. Diabetes Nutr Metab. 15 (2002) 152-159
49. Nyholm B., Orskov L., Hove K.Y., et al. The amylin analogue pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetesmellitus. Metabolism 48 (1999) 935-941
50. Ceriello A., Piconi L., Quagliaro L., et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 28 (2005) 632-637
51. Nogid A., and Pham D.Q. Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus. Phormocotheropy 26 (2006) 1626-1640
52. Edelman S., Garg S., Frias J., et al. A double-blind, placebocontrolled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 29 (2006) 2189-2195
53. Fuhlendorff J., Rorsman P., Kofod H., et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47 (1998) 345-351
54. Berger S., Strange P., and Repaglinide Study Group. Repaglinide, a novel oral hypoglycemic agent in type 2 diabetes: A randomized, placebo-controlled, double-blind fixed dose study. Diabetes 47 Suppl 1 (1998) A18
55. Ceriello A., Cavarape A., Martinelli L., et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: Effects of insulin aspart. Diabet Med. 21 (2004) 171-175
56. Ashwell S.G., Amiel S.A., Bilous R.W., et al. Improved glycaemic control with insulin glargine plus insulin lispro: A multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med. 23 (2006) 285-292
57. Kazda C., Hulstrunk H., Helsberg K., et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: A randomized controlled trial in pa tients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 20 (2006) 145-152
58. Dailey G., Rosenstock J., Moses R.G., and Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27 (2004) 2363-2368
59. Garg S.K., Ellis S.L., and Ulrich H. Insulin glulisine: A new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Phormocother 6 (2005) 643-651
60. [pub lished correction appears in Endocr Proct. 2005;11:145]. Garg S.K., Rosenstock J., and Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: Insulin glulisine versus regular human insulin in combination with basal insulinglargine. Endocr Proct. 11 (2005) 11-17
61. Barnett A.H., Dreyer M., Lange P., and Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin asadjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 29 (2006) 1282-1287
62. DeFronzo R.A., Bergenstal R.M., Cefalu W.T., et al., Exubera Phase III Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: A 12-week, randomized, comparative trial. Diabetes Care. 28 (2005) 1922-1928
63. Poon T., Nelson P., Shen L., et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: A dose-ranging study. Diabetes Technol Ther. 7 (2005) 467-477
64. Fehse F., Trautmann M., Holst J.J., et al. Exenatide augments firstand second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metob. 90 (2005) 5991-5997
65. Blonde L., Klein E.J., Han J., et al. Interim analysis of the effects of exenatide treatment on Al C. weight and cardiovascular risk factors over 82 weeks in 314 overweight patientswith type 2 diabetes. Diabetes Obes Metob. 8 (2006) 436-447
66. Ozyazgan S., Kutluata N., Afsar S., et al. Effect of glucagonlike peptide-1 (7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 74 (2005) 119-126
67. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 359 (2002) 824-830
68. Ahren B., Landin-Olsson M., Jansson P.A., et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metob. 89 (2004) 2078-2084
69. Pratley R., and Galbreath E. Twelve-week monotherapy with the DPP-4 inhibitor, LAF237 improves glycemic control in patients with type 2 diabetes (T2DM). Diabetes 53 (2004) A83
70. Pratley R.E., Jauffret-Kamel S., Galbreath E., and Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Harm Metob Res. 38 (2006) 423-428